Skip to main content
Premium Trial:

Request an Annual Quote

SeqWright to Use 454, NimbleGen Tools in Eli Lilly Collaboration

NEW YORK (GenomeWeb News) – Genomic services company SeqWright will use technologies from Roche subsidiaries 454 Life Sciences and NimbleGen to help drug developer Eli Lilly to identify genetic variants associated with psychiatric diseases, Roche said today.

Under the collaboration, SeqWright will use NimbleGen Sequence Capture technology to enrich around 40 megabases of the human genome, which will then be sequenced using 454 Life Sciences Genome Sequencer FLX System.

Eli Lilly's Brian Edmonds, a research advisor for global external research and development, in a statement called the genomic studies "a way to better examine the root causes of various psychiatric diseases. If this project delivers as expected, we hope to identify new biomarkers or novel drug targets for future development of medicines to treat an array of psychiatric illnesses."

Roche did not specify which psychiatric diseases the research would focus on.

Financial terms of the agreement were not released.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.